| Literature DB >> 33801636 |
Antia G Pereira1,2, Paz Otero1, Javier Echave1, Anxo Carreira-Casais1, Franklin Chamorro1, Nicolas Collazo1, Amira Jaboui1, Catarina Lourenço-Lopes1, Jesus Simal-Gandara1, Miguel A Prieto1,2.
Abstract
Algae are considered pigment-producing organisms. The function of these compounds in algae is to carry out photosynthesis. They have a great variety of pigments, which can be classified into three large groups: chlorophylls, carotenoids, and phycobilins. Within the carotenoids are xanthophylls. Xanthophylls (fucoxanthin, astaxanthin, lutein, zeaxanthin, and β-cryptoxanthin) are a type of carotenoids with anti-tumor and anti-inflammatory activities, due to their chemical structure rich in double bonds that provides them with antioxidant properties. In this context, xanthophylls can protect other molecules from oxidative stress by turning off singlet oxygen damage through various mechanisms. Based on clinical studies, this review shows the available information concerning the bioactivity and biological effects of the main xanthophylls present in algae. In addition, the algae with the highest production rate of the different compounds of interest were studied. It was observed that fucoxanthin is obtained mainly from the brown seaweeds Laminaria japonica, Undaria pinnatifida, Hizikia fusiformis, Sargassum spp., and Fucus spp. The main sources of astaxanthin are the microalgae Haematococcus pluvialis, Chlorella zofingiensis, and Chlorococcum sp. Lutein and zeaxanthin are mainly found in algal species such as Scenedesmus spp., Chlorella spp., Rhodophyta spp., or Spirulina spp. However, the extraction and purification processes of xanthophylls from algae need to be standardized to facilitate their commercialization. Finally, we assessed factors that determine the bioavailability and bioaccesibility of these molecules. We also suggested techniques that increase xanthophyll's bioavailability.Entities:
Keywords: algae; bioactive; carotenoids; health; natural compounds; xanthophylls
Year: 2021 PMID: 33801636 PMCID: PMC8067268 DOI: 10.3390/md19040188
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Positive effects on human health and industrial applications of carotenoids from natural sources.
Xanthophylls in algae: mass production, concentration, and application.
| Mol. | Algae | Extraction | Concentration | Applications | Ref. |
|---|---|---|---|---|---|
|
|
| Enzyme-assisted extraction | 0.66 mg/g DW | Development of value-added nutraceutical products from seaweed | [ |
|
| Supercritical fluid extraction | 2.18 mg/g DW | Obtaining high-purity fucoxanthin | [ | |
|
| Microwave-assisted extraction | 0.04 mg/g DW | Obtaining high-purity fucoxanthin | [ | |
|
| Maceration | 0.10 mg/g DW | Drug against chronic kidney disease | [ | |
|
| Microwave-assisted extraction | 0.90 mg/g DW | Obtention of high-purity fucoxanthin | [ | |
|
| Maceration | 3.09 mg/g DW | Scones | [ | |
|
| Supercritical fluid extraction | 0.99 mg/g DW | Carotenoid isolation | [ | |
|
| Maceration | 2.67 mg/g DW | Drug development | [ | |
|
| Ultrasonic-assisted extraction | 0.75 mg/g DW | Nutraceuticals and biomedical applications | [ | |
|
| Maceration | 3.47 mg/g DW | Optimization of the environmental conditions | [ | |
|
| Maceration | 18.60 mg/g DW | Commercial fucoxanthin production | [ | |
|
| Ultrasonic-assisted extraction | 0.25 mg/g DW | Nutraceutical, cosmetic and pharmaceutical applications, such as for the treatment of metastatic melanoma | [ | |
|
| Ultrasonic-assisted extraction | 0.03 mg/g DW | Yogurt | [ | |
|
| Maceration | 0.1 mg/g DW | Milk | [ | |
|
|
| Conventional extraction | 900 kg/2 ha/year | Antioxidant, anti-tumor, anti-inflammatory, ocular protective effect, antidiabetic, coloring agent | [ |
|
| Two-stage system | 3.8% dw | [ | ||
|
| Enzyme | 3.6% dw | [ | ||
|
| Conventional extraction | 2–3% dw | [ | ||
|
| Pressurized extraction | 99% of total AS | [ | ||
|
|
| Maceration | 83.8 mg/L | Antioxidant, light-filtering, eye protection, colorant, potential therapeutic use against several chronic diseases, lower risk of cancer, anti-inflammatory benefits | [ |
|
| Mechanical | 83.8 mg/L | [ | ||
|
| Mechanical | 4.92 mg/g | [ | ||
|
| Heptane–ethanol–water extraction | 30 mg/g | [ | ||
|
| - | 0.54% wt | [ | ||
|
| Conventional extraction | 15.4 mg m−2 d−1 | [ | ||
|
|
| Supercritical fluids extraction | 13.17 mg/g | Antioxidant, anti-inflammatory, eyes and UV light protection, prevention of coronary syndromes, anti-tumoral, anti-cardiovascular diseases, and structural actions in neural tissue | [ |
|
| Pressurized liquid extraction | 4.26 mg/g | [ | ||
|
| Pulse electric field | 1.64 mg/g | [ | ||
|
| Pulse electric field | 0.13 mg/g | [ | ||
|
| Moderate electric field | 244 µg/g | [ | ||
|
|
| Supercritical fluid extraction | 7.5 mg/100 g | Antioxidant, anti-inflammatory, anticancer (lung, oral, pharyngeal), improves respiratory function, stimulation of bone formation and protection, modulation response to phytosterols in post-menopausal women, decreases risk of degenerative diseases | [ |
|
| Conventional extraction | 14.2% total carotenoids | [ | ||
|
| Conventional extraction | 10.2% total carotenoids | [ | ||
|
| Maceration | 2.38 µg/g DW | [ | ||
|
| Enzyme extraction | - | [ | ||
|
|
| Maceration | 16 mg/kg fresh algae | Anti-angiogenic, antioxidant, cancer-preventing action; inhibit adipogenesis | [ |
|
| Maceration | 0.1% DW | [ | ||
|
| Maceration | 0.1% DW | [ | ||
|
|
| MeOH extraction | 19% of total pigments | Antioxidant | [ |
|
| MeOH extraction | - | [ | ||
|
| EtOH extraction | 10% total carotenoids | [ | ||
|
| Whole | 14 µg/L | [ | ||
|
|
| MeOH extraction | 17% of total pigments | Antioxidant | [ |
Mol: Molecules/compounds; FU: Fucoxanthin; AS: Astaxanthin; LU: Lutein; ZEA: Zeaxanthin; CRY: β-cryptoxanthin; SIP: Siphonaxanthin; DIAD: Diadinoxanthin; DIAT: Diatoxanthin. dw: Dry weight.
Figure 2Chemical structure of the main xanthophylls present in algae [82].
Delivery systems used to increase marine carotenoids’ bioavailability.
| Mol. | Delivery System | Assay | Benefits | Results | Use | Ref. |
|---|---|---|---|---|---|---|
|
| Palm stearin solid lipid core | In vitro | Increase stability during storage | Release of FU of 22.92% during 2 h in SGF and 56.55% during 6 h SIF | Oral supplements | [ |
| Nanoparticles of zein | ABTS DPPH | Increase antioxidant activity | More antioxidant than free FU | Foods and beverages | [ | |
| Nanoemulsion | In vitro | Increase stability during storage; antiobesity | 95% of FU remains in the emulsion after 4 weeks | Food, beverages, nutraceutics | [ | |
| Nanoemulsion (LCT) | In vitro digestion and bioability assays in rats | Increase stability | Increase FU level in serum blood (LCT > MCT) | Functional foods and nutraceutics | [ | |
| Chitosan–glycolipid nanogels | In vitro | Significant increase in bioavailability | Lpx levels (nmol MDA/mL) higher in control (30.9) than in emulsions (17.0–12.15) | Foods and nutraceutics | [ | |
|
| Fish oil | In vitro | Useful for supplementation | Better antioxidant effect | Oral supplements | [ |
| Encapsulation | TBARS Peroxide enzymes | Increase stability | Better antioxidant effect | Foods | [ | |
| Pectin–chitosan multilayer | Stability Assays | Increase stability | Better stability than monolayer | Nutraceuticals, functional, medical foods | [ | |
| Release and stability test | Increase stability | Enhance stability | Functional foods and nutraceutics | [ | ||
| Ascobyl palmitate emulsion | Stability assay | Sublingual delivery | Enhance sports performance, skin protection, cardioprotective | Dietetic supplementation in sports | [ | |
|
| β-CD | In vitro | Increase stability | More stable against oxidating agents | Foods | [ |
| Glycyrrhizic acid, arabinogalactan | In vitro | Solubility enhancement | Prevention of H-aggregates formation, increase of photostability | Foods | [ | |
|
| Sea Buckthorn oil and water emulsion | Stability and digestive assays | Increase bioaccesibility | Increase 64.55% | Functional foods and nutraceutics | [ |
| High-pressure treatment | Stability and digestive assays | Improve | Foods | [ | ||
| Glycyrrhizic acid, arabinogalactan | In vitro | Solubility enhancement | Prevention of H-aggregates formation, increase of photostability | Foods | [ |
SGF: Simulated gastric fluid; SIF: Simulated intestinal fluid; LCT: Long-chain triglycerides; MCT: Medium-chain triglycerides.
Figure 3Uptake, transport, and secretion pathways of marine carotenoids in the human body.
Summary of studies and meta-analysis on the health-related properties and effects of carotenoids and observed results.
| Study | Model | Dose | Experimental Design | Observations | Ref. |
|---|---|---|---|---|---|
|
| |||||
| Anti-inflammatory | In vitro. RAW 264.7 macrophages with LPS-induced inflammation | 15–60 μM | Expression of inflammatory mediators | D-d reduction of expression of IL6-IL-1, NO, and TNF-α | [ |
| In vitro (Apo-9′). RAW 264.7 macrophages and zebrafish model | 25–100 μg/mL | Reduction of LPS-induced inflammation | D-d reduction of NO, ROS, TNF-α, and COX production | [ | |
| In vitro and in vivo. RAW 264.7 and aqueous humor of rats | 10 mg/kg | Reduction of LPS-induced inflammation | D-d reduction of PGE2, NO, TNF-α by inhibiting iNOS and COX-2 | [ | |
| Anti-cancer | Ex vivo. B16F10 cell culture implanted in mice | 200 μM | Growth inhibition of melanoma | D-d growth inhibition by inducing G0/G1 cell cycle arrest and apoptosis; inhibition production of retinoblastoma protein | [ |
| In vitro. Human leukemic HL-60 cells | 15.2 μM | Inhibited the proliferation | DNA fragmentation | [ | |
|
| |||||
| Anti-inflammatory | In vitro. RAW 264.7, splenocytes, and bone-narrow macrophages | 25 μM | Expression of inflammatory mediators in LPS-induced inflammation | D-d significant reduction of IL-6, IL-1β, and ROS production | [ |
| In vivo. Mice with induced acute lung injury | 60 mg/kg/day for 14 days | Analysis of inflammation markers, tissue damage | Significant reduction of mortality, histological damage, inflammatory infiltration, and iNOS and NF-κβ levels | [ | |
| Anti-cancer | In vitro. Human colon cancer lines HCT-116, SW480, WiDr, HT-29 and LS-174 | 5–25 µg/mL | Growth inhibition of with | D-d cell cycle arrest and apoptosis induction by lowering expression of Bcl-2, AKT and induced expression of apoptotic MAPK | [ |
| In vivo. Chemically induced colitis and colon carcinogenesis mice | 200 ppm | Analysis of inflammatory biomarkers | D-d inhibition of NF-κβ, TNF-α, IL-1β, IL-6, and COX-2 expression; lower iNOS expression at high dosage | [ | |
|
| |||||
| Anti-inflammatory | Observational study. Early atherosclerosis patients ( | 20 mg/day for 3 months | Differences in serum cytokines, and metabolic biomarkers | Significant reduction in serum IL-6 MCP-1 and LDL-cholesterol after 3 months of supplementation | [ |
| Observational study. Preterm infants ( | 30 mL/ kg/ day until 40 weeks post-menstrual age | Differences in inflammation biomarkers | Enhanced retinal development and reduced C-reactive protein levels | [ | |
| Anti-cancer | In vivo. Rats | 3–30 g/L | Inhibition of N-methylnitrosourea-induced colon crypt foci formation | Significantly lowered formation of aberrant crypt foci | [ |
|
| |||||
| Anti-cancer | Prospective cohort study. Smokers and non-smokers from NHANES III ( | Dietary contribution | 20-year cohort | Higher serum levels of β-CRY were associated with lower death risk, but not for non-smokers | [ |
| Ex vivo. Human gastric cell lines AGS and SGC-7901 implanted in mice | 0–40μM | Growth and proliferation inhibition | D-d growth and proliferation inhibitory activity by reducing cyclins, endothelial growth factor, PKA and increasing cleaved caspases expression | [ | |
| In vivo. Mice | 10 mg/kg diet | Induced emphysema and lung tumorigenesis | D-d tumor mass reduction, decreased levels of IL-6 and AKT and restoration of silenced tumor-suppressor genes | [ | |
| In vivo. Cigarette smoke-exposed ferrets | 7.5–37.5 μg/kg/day | Inflammation biomarkers and tissue damage analysis | D-d inhibition of NF-κβ, TNF-α, AP-1 expression as well as lung tissue squamous metaplasia and inflammation | [ | |
|
| |||||
| Anti-cancer | In vitro. Human leukemia (HL-60) cells | 5–20 μM | Analysis on cell viability and apoptosis | D-d reduction of cell viability and induction of apoptosis by increasing levels of DR5, lower expression of Bcl-2 and increase in caspase-3 | [ |
D-d: Dose-dependent; LPS: Lipoplysaccharide, ROS: Reactive oxygen species, IL: Interleukin, NRF2: Nuclear factor E2-related factor 2, PKA: Protein kinase A, AKT: Protein kinase B, ERK: Extracellular signal-regulated kinase, PAI-1: Plasminogen activator inhibitor-1, MMP: Metalloproteinases, Bcl-2: B-cell lymphoma 2, PG: Prostaglandin, RR: Relative risk, CI: Confidence interval.